COR

CencoraNYSE · Health Care Distributors · Health Care

Previous close

330.84

Change

+0.31 / +0.09%

FinDog View

Bullish

52-Week Range ?

244.82 – 377.54

P/E (TTM) ?

24.0

Forward P/E ?

15.9

Based on consensus earnings for the next 12 months

Market Cap

$63.7B

+10.19%

S&P 500 −0.91% over same period

Volume / Avg Volume

1.3M / 1.1M

1.21× average

Latest earnings analysisFY2026 Q3Reported 2026-08-05

Cencora Q3 FY2026: revenue $84.75B, adjusted EPS $4.48, outlook raised

Cencora beat the $4.3924 consensus adjusted EPS estimate with $4.48 and nudged full-year guidance up to $17.75–$17.95, so the quarter reads Bullish. The catch is mix: revenue rose 5.1% to $84.75 billion while $95.74 of every $100 of revenue still goes straight to product cost. OneOncology lifted gross margin and also added debt.

Read the full analysis →

Revenue$84.75BYoY +5.10%

EPS (non-GAAP)$4.48Beatest. $4.39

Next-day move+2.46%

Price History

Closing price · USD1M 6M 1Y 5Y

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 35.01M 6M 1Y 5Y

Recent Earnings

Click to read the FinDog analysis

Period	Reported	Revenue	EPS Actual / Est.	Next-Day Move	Analysis
FY2026 Q3 Quarter ended 2026-06	2026-08-05	$84.8B	4.48 / 4.39	+2.46%	Read analysis →
FY2026 Q2 Quarter ended 2026-03	2026-05-06	$78.4B	4.75 / 4.86	+1.16%	Pending
FY2026 Q1 Quarter ended 2025-12	2026-02-04	$85.9B	4.08 / 4.08	+6.72%	Pending
FY2025 Q4 Quarter ended 2025-09	2025-11-05	$321B	3.84 / 3.82	+1.76%	Pending
FY2025 Q3 Quarter ended 2025-06	2025-08-06	$80.7B	4.00 / —	−1.90%	Pending
FY2025 Q2 Quarter ended 2025-03	2025-05-07	$75.5B	4.42 / —	−6.83%	Pending

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →

Report date

2026-11-04

in 3 days · After hours

Consensus EPS

$4.62

Last quarter EPS $4.48

Avg. next-day move over the last 6 reports

±3.5%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data

Valuation

P/E is at percentile 23 of its 5-year rangeCheap

5-year range 21.7 – 43.7 · Median 26.4

Last 4 quarters: $71,000 in buybacks + $468M in dividends, 0.73% of market cap combined

P/E (TTM)

24.0

P/B

20.7

P/S

0.2

Dividend Yield

1.01%

Earnings Reaction

Over the last 6 reports, the stock moved ±3.5% on average on the first trading day after, rising 4 times

Most recent +2.46%

Volatility & Correlation

1-year beta -0.15 · Correlation with S&P 500 -0.06Low beta

Annualized volatility 31% vs. 13% for the S&P 500

Insider Trading

View all →

Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions

Buy 0 · $0.00MSell 4 · $4.7MNet selling $4.7M

10-01Krikorian LazarusSVP & Chief Accounting OfficerSell$0.30M986 shares · Avg price 303.18
09-16GREENBERG LON RDirectorSell$0.41M1,280 shares · Avg price 321.30
09-01Krikorian LazarusSVP & Chief Accounting OfficerSell$0.32M985 shares · Avg price 325.97
08-24Campbell Elizabeth SExecutive Vice PresidentSell$3.7M11,300.471 shares · Avg price 324.12

Multi-Quarter Financial Trends

View all quarters →

Last 12 quarters · As reported by the company

Quarter	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Free Cash Flow ($B)	EPS
FY2026 Q3	84.75	+5.1%	4.3%	1.12	0.76	2.43	3.94
FY2026 Q2	78.36	+3.8%	4.6%	1.14	1.64	1.17	8.40
FY2026 Q1	85.93	+5.5%	3.6%	0.76	0.56	-2.42	2.87
FY2025 Q4	83.73	+5.9%	3.5%	0.02	-0.34	2.88	-1.74
FY2025 Q3	80.66	+8.7%	3.6%	0.87	0.69	-0.07	3.52
FY2025 Q2	75.45	+10.3%	4.1%	1.04	0.72	3.22	3.68
FY2025 Q1	81.49	+12.8%	3.1%	0.71	0.49	-2.82	2.50
FY2024 Q4	79.05	+14.7%	3.2%	0.13	0.00	0.82	0.04
FY2024 Q3	74.24	+10.9%	3.2%	0.67	0.48	2.36	2.42
FY2024 Q2	68.41	+7.8%	3.7%	0.55	0.42	-0.99	2.09
FY2024 Q1	72.25	+15.0%	3.4%	0.82	0.60	0.81	2.98
FY2023 Q4	68.92	+12.7%	3.3%	0.48	0.35	1.65	1.72

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →

Ticker	Company	Market Cap	P/E	Revenue YoY	Gross Margin	1M	View
COR	Cencora	$63.7B	24.0	+5.1%	4.3%	+10.19%	Bullish
LLY	Lilly (Eli)	$1.34T	50.2	+38.6%	83.9%	+22.51%	Bullish	Compare
JNJ	Johnson & Johnson	$666B	41.3	+5.9%	68.1%	+3.20%	Bullish	Compare
ABBV	AbbVie	$522B	81.4	+10.2%	74.7%	+12.73%	Bullish	Compare
UNH	UnitedHealth Group	$367B	23.0	+0.4%	88.1%	+10.87%	Bullish	Compare
MRK	Merck & Co.	$371B	117.2	+5.1%	73.5%	+2.90%	Neutral	Compare
TMO	Thermo Fisher Scientific	$258B	36.4	+9.1%	—	+3.25%	Neutral	Compare
AMGN	Amgen	$254B	28.5	+9.5%	72.0%	+10.56%	Bullish	Compare
GILD	Gilead Sciences	$213B	—	+6.8%	81.1%	+14.51%	Neutral	Compare

The View in One Line

Revenue $84.75B +5.1%, adjusted EPS beat ~2%, guidance raised, $1B buyback; 4.3% gross margin and rising debt are risks, still bullish.

Updated 2026-10-30

View History

09-17Neutral → Bullish
Revenue +5.1%, adjusted EPS beat ~2%, guidance raised, $1bn buyback; 4.3% gross margin and rising debt are risks, but still bullish.

Notable Institutional Holders

Citadel Advisors · Ken Griffin$387MAdded +71%
Bridgewater Associates · Ray Dalio$9.6MAdded +139%
Renaissance Technologies$6.7M

As of 2026-06-30

ETFs holding it

XLV Health Care Select Sector SPDR Fund0.94%
VIG Vanguard Dividend Appreciation ETF0.27%
RSP Invesco S&P 500 Equal Weight ETF0.22%
VTV Vanguard Value ETF0.22%
VOO Vanguard S&P 500 ETF0.10%
IVV iShares Core S&P 500 ETF0.10%
SPY SPDR S&P 500 ETF Trust0.10%
VTI Vanguard Total Stock Market ETF0.08%

Weights estimated at latest prices

Key Events

09-25Management Change
Cencora Appoints Robert E. Sanchez to Board of Directors
Cencora appointed Robert E. Sanchez to its board effective October 1, 2026, increasing the board from ten to eleven members.Source ↗
08-14Management Change
Director Lorence H. Kim Resigns Due to New Role
On August 13, 2026, director Lorence H. Kim resigned immediately to become Chief Financial Officer of Commonwealth Fusion Systems, with no disagreement with the company.Source ↗
08-05Capital Actions
Cencora Increases Revolving Credit Facility to $7 Billion and Extends to 2031
On July 31, 2026, Cencora raised its multi-currency revolving credit commitments from $5.5 billion to $7 billion and extended the maturity to July 2031.Source ↗
06-15Management Change
Cencora CHRO Retires, Hammock Succeeds
Cencora announced that EVP and Chief Human Resources Officer Silvana Battaglia will retire on July 12, 2026, with former Verizon executive Samantha L. Hammock succeeding her on July 13.Source ↗
05-29Management Change
Cencora Appoints New CFO
Eva C. Boratto will become Executive Vice President and CFO on June 29, 2026, succeeding the retiring James F. Cleary, with an annual salary of $1 million.Source ↗

Key Financial Trends

Quarterly Revenue ($B)84.8

Gross Margin4.3%

Free Cash Flow ($B)2.4